Bayer began construction of a US$59 million production and supply plant on Wednesday to expand its existing site in Beijing to enhance a stable supply of prescription drugs.
New production lines are expected to become operational by the end of 2022 and are set to increase the annual output of the Beijing site by about 40 percent.
Managing chronic disease is a key segment of the "Healthy China 2030" blueprint, and a detailed action plan was released by the State Council last July.
Ensuring a continuous supply of commonly used drugs for chronic diseases at an accessible price has been the focus of China's drug administration body and major drug companies.
Bayer has launched a 50-million-euro (US$59 million) expansion project for its production and supply facilities in Beijing.
Bayer Pharmaceuticals established its first plant in the Beijing Economic-Technological Development Area in 1995 and has been producing a wide range of treatments for diabetes, hypertension and other cardiovascular diseases.
In 2016, it became the largest pharmaceuticals packaging site in Bayer Pharmaceuticals Division’s global production network.
The expansion project covers production space and auxiliary technical area, which will be equipped with automated production lines and a logistics facility.